MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 48 filers reported holding MERSANA THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $2,395,000 | +42.9% | 90,000 | 0.0% | 0.02% | +18.8% |
| Q3 2020 | $1,676,000 | -20.4% | 90,000 | 0.0% | 0.02% | -27.3% |
| Q2 2020 | $2,106,000 | +222.5% | 90,000 | -78.2% | 0.02% | +214.3% |
| Q3 2019 | $653,000 | -93.5% | 413,525 | -83.2% | 0.01% | -92.7% |
| Q2 2019 | $9,981,000 | -41.0% | 2,464,415 | -23.4% | 0.10% | -39.6% |
| Q1 2019 | $16,916,000 | +104.5% | 3,216,002 | +58.6% | 0.16% | +82.8% |
| Q4 2018 | $8,272,000 | -55.1% | 2,027,505 | +10.2% | 0.09% | -43.5% |
| Q3 2018 | $18,403,000 | -17.6% | 1,840,333 | +47.1% | 0.15% | -24.9% |
| Q2 2018 | $22,342,000 | +51.9% | 1,250,977 | +34.2% | 0.20% | +39.5% |
| Q1 2018 | $14,704,000 | -0.5% | 932,396 | +3.6% | 0.15% | -2.0% |
| Q4 2017 | $14,783,000 | +79.0% | 899,773 | +88.4% | 0.15% | +59.6% |
| Q3 2017 | $8,260,000 | +68.9% | 477,711 | +36.5% | 0.09% | +54.1% |
| Q2 2017 | $4,890,000 | – | 350,000 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SILVERARC CAPITAL MANAGEMENT, LLC | 5,000,000 | $6,350,000 | 1.92% |
| VR Adviser, LLC | 11,328,000 | $14,386,560 | 1.51% |
| Bain Capital Life Sciences Investors, LLC | 8,663,673 | $11,002,865 | 1.23% |
| Affinity Asset Advisors, LLC | 2,850,000 | $3,619,500 | 1.02% |
| EcoR1 Capital, LLC | 19,364,688 | $24,593,154 | 0.83% |
| Altium Capital Management LP | 1,059,136 | $1,345,103 | 0.70% |
| 5AM Venture Management, LLC | 1,305,000 | $1,657,350 | 0.48% |
| Decheng Capital Management III (Cayman), LLC | 904,268 | $1,148,420 | 0.38% |
| COMMODORE CAPITAL LP | 2,244,378 | $2,850,360 | 0.33% |
| Philosophy Capital Management LLC | 2,342,634 | $2,975,145 | 0.32% |